Ametek Inc/ (AME) Stock Analysis and Metrics

Ametek

NYSE: AME

$242.10 ▲ +0.96 (+0.40%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap55.40 Bn

P/E36.26

P/S7.29

Div. Yield0.01

ROIC (Qtr)0.00

Total Debt (Qtr)2.18 Bn

Revenue Growth (1y) (Qtr)11.34

Add ratio to table…

About

AMETEK, Inc. is a leading global manufacturer of electronic instruments and electromechanical devices. The company designs produces and markets a broad range of products for industrial aerospace medical and process markets. Its operations span North America Europe Asia and South America serving customers worldwide. AMETEK, Inc. leverages deep engineering expertise to deliver high precision solutions that meet stringent performance requirements.

Revenue is generated primarily through the sale of electronic instruments and electromechanical components to a diverse set of end users. The electronic instruments group supplies analytical test measurement and monitoring equipment for power generation pharmaceutical semiconductor and food and beverage industries. The electromechanical group provides precision motion control solutions medical devices thermal management systems and specialty metal products. Sales are made directly to original equipment manufacturers distributors and through a global network of sales representatives. The company benefits from a balanced geographic mix with roughly half of its sales originating outside the United States.

The company operates through the following segments: Electronic Instruments (EIG) and Electromechanical (EMG).

• Electronic Instruments (EIG) focuses on the design and manufacture of advanced analytical test and measurement instruments for process power industrial aerospace medical and research markets. Its product portfolio includes process analyzers emission monitors spectrometers elemental and surface analysis instruments pressure and temperature sensors radiation detection devices and precision metrology equipment. EIG also supplies aircraft engine sensors power quality monitors uninterruptible power systems and data acquisition tools for aerospace and power generation applications.

• Electromechanical (EMG) provides precision motion control solutions highly engineered medical components thermal management systems specialty metals and electrical interconnects. Its offerings consist of brushless motors pumps heat exchangers surgical instruments implantable devices and connectors for harsh environments. EMG also operates a global network of aviation maintenance repair and overhaul facilities serving commercial and military aircraft.

Within its served markets AMETEK, Inc. holds strong positions in niche segments where it competes on technology quality and service. The electronic instruments group faces competition from established players in analytical instrumentation but maintains leadership through proprietary sensor technology and deep customer relationships. The electromechanical group contends with firms supplying motion control and medical devices yet differentiates via its expertise in miniaturization and material science. Overall the company benefits from a diversified portfolio that reduces reliance on any single market and enables cross selling of complementary technologies. Continuous investment in research development and lean manufacturing further strengthens its competitive advantage.

AMETEK, Inc. serves a broad base of customers including original equipment manufacturers contract manufacturers and end users in industrial aerospace medical and process sectors. Its electronic instruments are used by pharmaceutical companies semiconductor fabs power utilities and food and beverage processors. The electromechanical division supplies medical device makers automotive suppliers defense contractors and industrial automation firms. No single customer accounts for more than a small fraction of sales with the top five customers representing roughly four percent of EIG sales and fifteen percent of EMG sales. This diversified customer base reduces concentration risk and supports stable revenue streams. The company maintains long term relationships with many of its key accounts through collaborative product development and responsive service.

Investment Thesis

▲ Bull case

AMETEK's acquisition of Indicor Instrumentation represents a transformative strategic move that the market may be underestimating, with the $5.0 billion deal adding a high-quality portfolio of businesses generating approximately $1.1 billion in annual sales and profitability levels consistent with AMETEK's own. This acquisition significantly expands AMETEK's scale and capabilities within its Electronic Instruments Group (EIG) and Electromechanical Group (EMG), integrating mission-critical instrumentation businesses that serve attractive industrial and scientific end markets with recurring revenue streams from consumables, services, and aftermarket support. The deal aligns closely with AMETEK's growth model of operational excellence, technology innovation, global expansion, and strategic acquisitions, positioning the company to leverage its disciplined integration approach to unlock synergies and drive long-term value creation. Given AMETEK's strong financial capacity—highlighted by its ability to deploy well over $5 billion in capital while maintaining an investment-grade credit rating—and its proven track record of successful acquisitions without goodwill write-offs, Indicor could become a major catalyst for sustained earnings growth beyond current guidance ranges.
The breadth and durability of AMETEK's order backlog, which reached a record $3.87 billion in Q1 FY26 driven by 22% organic orders growth, signal robust underlying demand that may be underappreciated by investors focused solely on quarterly sales figures. This backlog strength is broad-based across all divisions, with notable strength in defense, space, power, semiconductor, and aerospace markets—areas where AMETEK holds differentiated technology positions in mission-critical applications. The company's ability to win large, multi-year contracts in sectors like nuclear submarines, UAV programs, and low-earth-orbit satellite components reflects deep customer trust and high switching costs due to stringent regulatory and compliance requirements. Unlike temporary cyclical upswings, this order strength is supported by secular trends such as defense modernization, AI-driven semiconductor tooling demand, and data center power infrastructure needs, suggesting that AMETEK's revenue visibility and growth trajectory are more secure than current guidance implies.
AMETEK's core operating margin expansion of 160 basis points in Q1 FY26, particularly the 410 basis point surge in EMG margins to 26%, reveals operating leverage and efficiency gains that may be underestimated in forward-looking guidance. The company reported core incrementals greater than 50% on both the company-wide and segment levels, indicating that each additional dollar of sales is converting to operating income at a highly efficient rate—far exceeding the 35% incremental margin assumption embedded in its full-year guidance. This outperformance is driven by productivity improvements, sales growth leverage in high-margin niches like automation and engineered solutions, and disciplined cost management, with EMG benefiting from strong sales growth in aerospace and defense MRO and proprietary parts businesses. Given AMETEK's history of conservative guidance and its ability to consistently exceed expectations through operational excellence, the market may not be fully pricing in the potential for margin expansion to accelerate beyond current estimates as the company scales its integrated operations.

AMETEK's acquisition of Indicor Instrumentation represents a transformative strategic move that the market may be underestimating, with the $5.0 billion deal adding a high-quality portfolio of businesses generating approximately $1.1 billion in annual sales and profitability levels consistent with AMETEK's own. This acquisition significantly expands AMETEK's scale and capabilities within its Electronic Instruments Group (EIG) and Electromechanical Group (EMG), integrating mission-critical instrumentation businesses that serve attractive industrial and scientific end markets with recurring revenue streams from consumables, services, and aftermarket support. The deal aligns closely with AMETEK's growth model of operational excellence, technology innovation, global expansion, and strategic acquisitions, positioning the company to leverage its disciplined integration approach to unlock synergies and drive long-term value creation. Given AMETEK's strong financial capacity—highlighted by its ability to deploy well over $5 billion in capital while maintaining an investment-grade credit rating—and its proven track record of successful acquisitions without goodwill write-offs, Indicor could become a major catalyst for sustained earnings growth beyond current guidance ranges.
The breadth and durability of AMETEK's order backlog, which reached a record $3.87 billion in Q1 FY26 driven by 22% organic orders growth, signal robust underlying demand that may be underappreciated by investors focused solely on quarterly sales figures. This backlog strength is broad-based across all divisions, with notable strength in defense, space, power, semiconductor, and aerospace markets—areas where AMETEK holds differentiated technology positions in mission-critical applications. The company's ability to win large, multi-year contracts in sectors like nuclear submarines, UAV programs, and low-earth-orbit satellite components reflects deep customer trust and high switching costs due to stringent regulatory and compliance requirements. Unlike temporary cyclical upswings, this order strength is supported by secular trends such as defense modernization, AI-driven semiconductor tooling demand, and data center power infrastructure needs, suggesting that AMETEK's revenue visibility and growth trajectory are more secure than current guidance implies.
AMETEK's core operating margin expansion of 160 basis points in Q1 FY26, particularly the 410 basis point surge in EMG margins to 26%, reveals operating leverage and efficiency gains that may be underestimated in forward-looking guidance. The company reported core incrementals greater than 50% on both the company-wide and segment levels, indicating that each additional dollar of sales is converting to operating income at a highly efficient rate—far exceeding the 35% incremental margin assumption embedded in its full-year guidance. This outperformance is driven by productivity improvements, sales growth leverage in high-margin niches like automation and engineered solutions, and disciplined cost management, with EMG benefiting from strong sales growth in aerospace and defense MRO and proprietary parts businesses. Given AMETEK's history of conservative guidance and its ability to consistently exceed expectations through operational excellence, the market may not be fully pricing in the potential for margin expansion to accelerate beyond current estimates as the company scales its integrated operations.

▼ Bear case

AMETEK's guidance for FY26 sales growth of high single digits and organic sales growth of mid-single digits may be overly optimistic given emerging signs of demand softening in key international markets, particularly Europe and Asia, which showed only low single-digit and low double-digit growth respectively in Q1 FY26. While U.S. performance remained strong, the company acknowledged modest headwinds from the Middle East due to disruptions that prevented approximately $15 million in orders from shipping, with management noting that rebuilding energy infrastructure will only occur "when this thing settles down"—indicating a lack of near-term visibility. Furthermore, the medical segment, which represents over 20% of AMETEK's exposure, is expected to deliver only mid-single-digit growth for the full year due to tough comparables later in 2026, despite strong Q1 results led by Paragon. This divergence between strong early-quarter results and cautious full-year outlook suggests that the company may be baking in anticipated weakness in medical and international markets that could weigh on overall growth if macroeconomic conditions deteriorate further.
The acquisition of Indicor Instrumentation, while strategically compelling, introduces significant execution and integration risks that the market may be overlooking, especially given the deal's size—approximately $5.0 billion in enterprise value—and its potential to strain AMETEK's operational focus and cultural cohesion. Although AMETEK has a history of successful bolt-on acquisitions, integrating a portfolio of businesses generating $1.1 billion in annual sales across EIG and EMG represents a far more complex undertaking than its typical deals, with risks including cultural misalignment, systems integration challenges, and potential distraction from core operations. Management emphasized that it avoids acquisitions half the size of AMETEK, yet Indicor represents roughly 15% of AMETEK's current $7.5 billion sales base and would significantly increase leverage, with gross debt-to-EBITDA already at 0.9x and net debt-to-EBITDA at 0.7x pre-deal. While the company maintains financial capacity to deploy over $5 billion while retaining investment-grade ratings, the incremental debt load and integration complexity could pressure margins and divert management attention, particularly if synergies fail to materialize as planned or if economic headwinds affect Indicor's end markets.
AMETEK's reliance on pricing power to offset inflationary and tariff-related cost pressures may be overstated, creating vulnerability if macroeconomic conditions shift or if customers push back on price increases in a softer demand environment. During the Q&A, management explicitly stated belief in its ability to "offset any inflationary costs with pricing" and to "offset inflation, including tariffs with pricing," but offered no concrete evidence of successful price realization in recent quarters beyond general margin expansion. This assumption becomes riskier given that core margin expansion in EIG was only 40 basis points despite strong orders growth, suggesting limited pricing flexibility in certain segments, while EMG's margin gains were heavily driven by sales volume leverage rather than pure pricing. If global industrial demand weakens—as hinted by subdued growth in Europe and modest headwinds in the Middle East—AMETEK may find it difficult to implement price increases without sacrificing volume, thereby compressing margins and undermining the incremental profitability assumptions underpinning its guidance.

AMETEK's guidance for FY26 sales growth of high single digits and organic sales growth of mid-single digits may be overly optimistic given emerging signs of demand softening in key international markets, particularly Europe and Asia, which showed only low single-digit and low double-digit growth respectively in Q1 FY26. While U.S. performance remained strong, the company acknowledged modest headwinds from the Middle East due to disruptions that prevented approximately $15 million in orders from shipping, with management noting that rebuilding energy infrastructure will only occur "when this thing settles down"—indicating a lack of near-term visibility. Furthermore, the medical segment, which represents over 20% of AMETEK's exposure, is expected to deliver only mid-single-digit growth for the full year due to tough comparables later in 2026, despite strong Q1 results led by Paragon. This divergence between strong early-quarter results and cautious full-year outlook suggests that the company may be baking in anticipated weakness in medical and international markets that could weigh on overall growth if macroeconomic conditions deteriorate further.
The acquisition of Indicor Instrumentation, while strategically compelling, introduces significant execution and integration risks that the market may be overlooking, especially given the deal's size—approximately $5.0 billion in enterprise value—and its potential to strain AMETEK's operational focus and cultural cohesion. Although AMETEK has a history of successful bolt-on acquisitions, integrating a portfolio of businesses generating $1.1 billion in annual sales across EIG and EMG represents a far more complex undertaking than its typical deals, with risks including cultural misalignment, systems integration challenges, and potential distraction from core operations. Management emphasized that it avoids acquisitions half the size of AMETEK, yet Indicor represents roughly 15% of AMETEK's current $7.5 billion sales base and would significantly increase leverage, with gross debt-to-EBITDA already at 0.9x and net debt-to-EBITDA at 0.7x pre-deal. While the company maintains financial capacity to deploy over $5 billion while retaining investment-grade ratings, the incremental debt load and integration complexity could pressure margins and divert management attention, particularly if synergies fail to materialize as planned or if economic headwinds affect Indicor's end markets.
AMETEK's reliance on pricing power to offset inflationary and tariff-related cost pressures may be overstated, creating vulnerability if macroeconomic conditions shift or if customers push back on price increases in a softer demand environment. During the Q&A, management explicitly stated belief in its ability to "offset any inflationary costs with pricing" and to "offset inflation, including tariffs with pricing," but offered no concrete evidence of successful price realization in recent quarters beyond general margin expansion. This assumption becomes riskier given that core margin expansion in EIG was only 40 basis points despite strong orders growth, suggesting limited pricing flexibility in certain segments, while EMG's margin gains were heavily driven by sales volume leverage rather than pure pricing. If global industrial demand weakens—as hinted by subdued growth in Europe and modest headwinds in the Middle East—AMETEK may find it difficult to implement price increases without sacrificing volume, thereby compressing margins and undermining the incremental profitability assumptions underpinning its guidance.

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Industrial Machinery

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEV	GE Vernova Inc.	270.93 Bn	28.46	6.55	2.79 Bn
2	ETN	Eaton Corp plc	156.55 Bn	39.19	5.50	21.05 Bn
3	PH	Parker-Hannifin Corp	124.04 Bn	35.64	5.91	9.58 Bn
4	CMI	Cummins Inc	91.66 Bn	34.29	2.70	6.89 Bn
5	EMR	Emerson Electric Co	82.90 Bn	67.34	4.53	13.36 Bn
6	ITW	Illinois Tool Works Inc	81.54 Bn	26.02	5.03	9.15 Bn
7	AME	Ametek Inc/	55.40 Bn	36.26	7.29	2.18 Bn
8	ROK	Rockwell Automation, Inc	51.78 Bn	53.05	5.88	3.69 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password